US2023364010A1PendingUtilityA1

Intranasal delivery of olanzapine by precision olfactory device

73
Assignee: IMPEL PHARMCEUTICALS INCPriority: Jan 5, 2018Filed: Jul 24, 2023Published: Nov 16, 2023
Est. expiryJan 5, 2038(~11.4 yrs left)· nominal 20-yr term from priority
Inventors:John D. HoekmanKelsey H. SatterlyInna DashevskyAditya R. Das
A61K 9/0043A61K 9/16A61K 31/5513A61M 15/003A61K 9/1652A61K 31/00A61P 25/18A61K 9/1623A61K 9/1617A61K 31/551A61K 9/0075A61K 9/0078A61M 2202/064A61M 15/08A61M 21/02A61M 2021/0077A61M 15/009A61M 2250/00A61M 2205/0238A61M 11/02A61M 15/0005A61M 15/0036A61M 11/006A61K 9/1635
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for acutely treating agitation in a subject, comprising:
 intranasally administering an effective dose of a dry pharmaceutical composition comprising olanzapine to a subject exhibiting agitation.

Join the waitlist — get patent alerts

Track US2023364010A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.